Takeda announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors, or VEGFR, -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer, or mCRC. The European Commission, or EC, will consider the CHMP opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union, Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Takeda, Astellas Pharma and Sumitomo Mitsui to establish joint venture company
- FDA Approves New Takeda Drug Delivery Option
- FDA approves subcutaneous administration of Takeda’s ENTYVI in Crohn’s disease
- Takeda Announces Issuance of Innovative Hybrid Bonds
- Takeda selects eight U.S. non-profit organizations as grant recipients
